The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.

Another $50,000 from tobacco giant Altria last month brings money raised to expand the Republican Party of Kentucky ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

The first sensational stock that can pad investment portfolios in 2025 is social media titan Meta Platforms (NASDAQ: META), ...

Aetna is taking legal action against Pfizer, Novartis, Teva Pharmaceuticals and others, saying the list of drugmakers ...

Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...

Three high-octane income stocks -- sporting an average yield of 7.93% -- can fatten investors' pocketbooks in the new year.

Pfizer (NYSE: PFE) is an interesting healthcare company with excellent prospects for cash flow growth. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

These are companies with “wide economic moats” and “significant advantages” that allow them to successfully fend off ...

Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...